Infections caused by extended-spectrum β-lactamase (ESBL)-producing bacteria become an emerging problem in the community setting in many parts of the world.
Objective
The objective of the study was to determine fecal carriage of ESBL-producing organisms in a community setting.
Methods
A total of 632 fecal specimens from healthy individuals were screened for ESBL using the agar screening test with MacConkey agar plates supplemented with 1 μg/mL of cefotaxime for selection of ESBL-producing strains and confirmed by the Clinical Laboratory Standards Institute combined disk method.
Results
Four hundred isolates (63.3%) were ESBL producers. Two hundred eighty-five isolates (71.25%) of them were Escherichia coli and 96 (24.0%) Klebsiella pneumoniae.
Conclusion
We concluded that the community could be a reservoir of these ESBL-producing bacteria and enzymes.
MolandSE, BlackJA, OuradaJ. Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrob Agents Chemother. 2002; 46: 3837–3842.
2.
BradfordPA.Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14: 933–951.
3.
Rodriguez-BañoJ, NavarroMD, RomeroL. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004; 42: 1089–1094.
4.
WoodfordN, WardME, KaufmannME. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004; 54: 735–743.
5.
HelalSF, WassefMA, BehiryIK. Detection of extended-spectrum beta lactamase (ESBL) in health care associated infections with Klebsiella species expressing SHV1 and/or TEM gene. Arab J Lab Med. 2011; 37 (2): 355–364.
6.
Performance Standards for Antimicrobial Susceptibility Testing: 10th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2009 (M100–S15).
7.
SchreckenbergerPC, JandaJM, WongJD. Algorism for identification of aerobic gram negative bacilli. In:MurrayPR, BaronEJ, JorgensenJH., eds.Manual of Clinical Microbiology. 9th ed. Washington, DC: ASM Press; 2009; 26: 438–441.
8.
High rates of intestinal colonization with extended-spectrum lactamase-producing Enterobacteriaceae in patients at a tertiary-care hospital in Israel. Presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, April 10-13, 2010, Vienna, Austria. Abstract P713.
9.
KaderAA, KamathKA.Faecal carriage of extended-spectrum β-lactamase-producing bacteria in the community. East Mediterr Health J. 2009; 15 (6): 1365.
10.
Abdul RahmanEM, El-SherifRH. High prevalence of antimicrobial resistance among bacterial pathogens of community-acquired urinary tract infection: impact on empiric therapy. Egypt J Lab Med. 2011. In press.
11.
KaderAA, KumarA.Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other Gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J. 2005; 26 (6): 956–959.
12.
KaderAA, KumarA.Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med. 2005; 25 (3): 239–242.
13.
WoodfordN, WardME, KaufmannME. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004; 54: 735–743.
14.
CormicanM, MorrisD, Corbett-FeeeneyG. Extended-spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community urinary tract infection. Diagn Microbiol Infect Dis. 1998; 32: 317–319.
15.
LucetJC, ChevretS, DecréD. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit epidemiology and risk factors for acquisition. Clin Infect Dis. 1996; 22: 430–436.
16.
MolandSE, BlackJA, OuradaJ. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother. 2002; 46: 3837–3842.
17.
LevinBR.Minimizing potential resistance: a population dynamics view. Clin Infect Dis. 2001; 33 (suppl 3): S161–S169.
18.
LivermoreDM.beta-Lactamase-mediated resistance and opportunities for its control. J Antimicrob Agents. 1998; 41: 25–41.
19.
BosiC, BosiC, Davin-RegliA. Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol. 1999; 37: 2165–2169.
20.
BontenMJ, SlaughterS, AmbergenAW. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med. 1998; 158: 1127–1132.
21.
ColodnerR, RockW, ChazanB. Risk factors for the development of extended-spectrum β-lactamase producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23: 163–167.
22.
HeseltineP.Has resistance spread to the community?Clin Microbiol Infect. 2000; 6: 11–16.
